News & Events zu Brainsway Ltd (BWAY)BWAYBrainsway Ltd

BrainsWay Q2 Revenue $12.77M, Raises 2026 Financial Guidance

Reports Q2 revenue $12.77M, consensus $16.54M. "This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in operating leverage. Revenue reached a record $17.1 million, Adjusted EBITDA more than doubled to $3.5 million, and we generated more than $6.0 million of operating cash flow. Record system shipments and RPO of $80.4 million further strengthen our visibility into continued growth," said Hadar Levy, Chief Executive Officer of BrainsWay. "We are seeing strong momentum across the business, which is fueled by expanding reimbursement coverage and increasing utilization throughout our installed base. As a result, we are raising our full-year financial guidance for 2026."

BrainsWay Raises FY26 Financial Guidance to $13M-$14M

Consensus $67.65M. Narrows FY26 adjusted EBITDA view to $13M-$14M from $12M-$14M. "This quarter marked our second consecutive quarter of approximately 35% revenue growth and further expansion in operating leverage. Revenue reached a record $17.1 million, Adjusted EBITDA more than doubled to $3.5 million, and we generated more than $6.0 million of operating cash flow. Record system shipments and RPO of $80.4 million further strengthen our visibility into continued growth," said Hadar Levy, Chief Executive Officer of BrainsWay. "We are seeing strong momentum across the business, which is fueled by expanding reimbursement coverage and increasing utilization throughout our installed base. As a result, we are raising our full-year financial guidance for 2026."

BrainsWay Presents New Data on Deep TMS for PTSD and Depression

BrainsWay announced the presentation of new real-world data demonstrating significant improvements in patients with comorbid post-traumatic stress disorder and Major Depressive Disorder treated with Deep Transcranial Magnetic Stimulation. This real-world data collection study evaluated the efficacy of Deep TMS as a tool to improve both PTSD and MDD symptoms in patients with comorbid disease. All 462 patients in the retrospective study, from 11 clinical sites, were diagnosed with both MDD and PTSD, received at least 20 Deep TMS treatment sessions using BrainsWay's H1 or H7 coils. Outcomes included changes in the PTSD Checklist for DSM-5 and the Patient Health Questionnaire-9 before and after treatment. Of these patients, 83.5% experienced a response, with an average 52% reduction in PCL-5 scores. Patients also experienced substantial improvements in depression symptoms, including a 66.6% response rate, a 27.3% remission rate, and an average 50% reduction in PHQ-9 scores.